Stifel reiterates Buy rating on Cooper Companies stock at $70
Stifel maintained a Buy rating on Cooper Companies (COO) with a $70 price target, citing competitive positioning and growth projections. The firm expects 3.1% growth for CooperVision by 2027 and mid-single-digit declines for Paragard. COO trades at a P/E of 19.67 and a PEG of 0.44, with a free cash flow yield above 7%. Recent earnings missed revenue expectations, leading to lowered guidance and mixed analyst reactions.
How this was made
The 30-second read
Why it matters
The new $70 target suggests Stifel sees upside relative to current price, which may trigger short‑term buying.
Market read
Analyst rating upgrades can move mid‑cap stocks; this update provides a fresh catalyst for COO.
What to watch
Potential litigation risk in fertility segment and slower growth in core lens market could temper upside.
Background
Stifel's reiteration follows a recent earnings miss and multiple downgrades from other banks, highlighting divergent analyst views.
Ticker impact
Stifel reiterated its Buy rating on Cooper Companies and set a new $70 price target, updating its outlook and valuation metrics.
likely upward pressure as investors price in the higher target and valuation appeal
Stifel's rating change is a fresh, material analyst action with a specific price target, providing a clear catalyst for short‑term buying.
Market effects
Positive outlook for the medical‑technology sector as a leading analyst raises expectations for Cooper Companies.
Limited to U.S. equities; no broader regional effect.
Minimal global impact beyond sector peers.
Counterpoint
Some analysts remain cautious due to recent earnings miss and competitive pressures on Paragard.
Key entities
- companyCooper Companies
Medical‑technology firm focused on contact lenses and fertility products.
- analystStifel
Equity research firm providing the rating and price target.
